Skip to main content
PMC home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(2):225–234. doi: 10.1016/j.nurx.2006.01.005

Therapeutics in Duchenne muscular dystrophy

Jonathan B Strober 1,2,3,✉
PMCID: PMC3593432  PMID: 16554260

Summary

Duchenne muscular dystrophy (DMD) is a fatal disorder affecting approximately 1 in 3500 live born males, characterized by progressive muscle weakness. Several different strategies are being investigated in developing a cure for this disorder. Until a cure is found, therapeutic and supportive care is essential in preventing complications and improving the afflicted child’s quality of life. Currently, corticosteroids are the only class of drug that has been extensively studied in this condition, with controversy existing over the use of these drugs, especially in light of the multiple side effects that may occur. The use of nutritional supplements has expanded in recent years as researchers improve our abilities to use gene and stem cell therapies, which will hopefully lead to a cure soon. This article discusses the importance of therapeutic interventions in children with DMD, the current debate over the use of corticosteroids to treat this disease, the growing use of natural supplements as a new means of treating these boys and provides an update on the current state of gene and stem cell therapies.

Key Words: Duchenne, muscular dystrophy, corticosteroids, gene therapy, stem cell therapy

References

  • 1.Beenakker EA, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients.Eur J Paediatr Neurol 2005. [DOI] [PubMed]
  • 2.Kroksmark AK, Beckung E, Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. Eur J Paediatr Neurol. 2001;5:191–198. doi: 10.1053/ejpn.2001.0510. [DOI] [PubMed] [Google Scholar]
  • 3.Merlini L, Bertini E, Minetti C, Mongini T, Morandi L, Angelini C, et al. Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve. 2004;29:548–552. doi: 10.1002/mus.20018. [DOI] [PubMed] [Google Scholar]
  • 4.Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005;58:151–155. doi: 10.1002/ana.20523. [DOI] [PubMed] [Google Scholar]
  • 5.Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology. 1989;39:475–481. doi: 10.1212/WNL.39.4.475. [DOI] [PubMed] [Google Scholar]
  • 6.Ansved T. Muscular dystrophies: influence of physical conditioning on the disease evolution. Curr Opin Clin Nutr Metab Care. 2003;6:435–439. doi: 10.1097/01.mco.0000078987.18774.D9. [DOI] [PubMed] [Google Scholar]
  • 7.Eagle M. Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord. 2002;12:975–983. doi: 10.1016/S0960-8966(02)00136-0. [DOI] [PubMed] [Google Scholar]
  • 8.de Lateur BJ, Giaconi RM. Effect on maximal strength of sub-maximal exercise in Duchenne muscular dystrophy. Am J Phys Med. 1979;58:26–36. [PubMed] [Google Scholar]
  • 9.Scott OM, Hyde SA, Vrbova G, Dubowitz V. Therapeutic possibilities of chronic low frequency electrical stimulation in children with Duchenne muscular dystrophy. J Neurol Sci. 1990;95:171–182. doi: 10.1016/0022-510X(90)90240-N. [DOI] [PubMed] [Google Scholar]
  • 10.Dubowitz V. Responses of diseased muscle to electrical and mechanical intervention. Ciba Found Symp. 1988;138:240–255. doi: 10.1002/9780470513675.ch15. [DOI] [PubMed] [Google Scholar]
  • 11.Do T. Orthopedic management of the muscular dystrophies. Curr Opin Pediatr. 2002;14:50–53. doi: 10.1097/00008480-200202000-00009. [DOI] [PubMed] [Google Scholar]
  • 12.Bach JR. The historical role of the physiatrist in the management of Duchenne muscular dystrophy. A commentary. Am J Phys Med Rehabil. 1996;75:239–241. doi: 10.1097/00002060-199605000-00020. [DOI] [PubMed] [Google Scholar]
  • 13.Schramm CM. Current concepts of respiratory complications of neuromuscular disease in children. Curr Opin Pediatr. 2000;12:203–207. doi: 10.1097/00008480-200006000-00004. [DOI] [PubMed] [Google Scholar]
  • 14.Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest. 1997;112:1024–1028. doi: 10.1378/chest.112.4.1024. [DOI] [PubMed] [Google Scholar]
  • 15.Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax. 1998;53:949–952. doi: 10.1136/thx.53.11.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Birnkrant DJ, Pope JF, Eiben RM. Management of the respiratory complications of neuromuscular diseases in the pediatric intensive care unit. J Child Neurol. 1999;14:139–143. doi: 10.1177/088307389901400301. [DOI] [PubMed] [Google Scholar]
  • 17.Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974;2:1409–1412. doi: 10.1016/S0140-6736(74)90071-3. [DOI] [PubMed] [Google Scholar]
  • 18.Siegel IM, Miller JE, Ray RD. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study. IMJ Ill Med J. 1974;145:32–33. [PubMed] [Google Scholar]
  • 19.Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol. 1987;44:812–827. doi: 10.1001/archneur.1987.00520200016010. [DOI] [PubMed] [Google Scholar]
  • 20.DeSilva S, Drachman DB, Mellits D, Kunel RW. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol. 1987;44:818–822. doi: 10.1001/archneur.1987.00520200022012. [DOI] [PubMed] [Google Scholar]
  • 21.Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med. 1989;320:1592–1597. doi: 10.1056/NEJM198906153202405. [DOI] [PubMed] [Google Scholar]
  • 22.Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.Cochrane Database Syst Rev 2004(2): p. CD003725. [DOI] [PubMed]
  • 23.Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991;48:383–388. doi: 10.1001/archneur.1991.00530160047012. [DOI] [PubMed] [Google Scholar]
  • 24.Fenichel GM, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 1991;48:575–579. doi: 10.1001/archneur.1991.00530180027012. [DOI] [PubMed] [Google Scholar]
  • 25.Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT, Griggs RC, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991;41:1874–1877. doi: 10.1212/WNL.41.12.1874. [DOI] [PubMed] [Google Scholar]
  • 26.Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology. 1993;43(3):520–527. doi: 10.1212/WNL.43.3_Part_1.520. [DOI] [PubMed] [Google Scholar]
  • 27.Sansome A, Royston P, Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul Disord. 1993;3:567–569. doi: 10.1016/0960-8966(93)90117-3. [DOI] [PubMed] [Google Scholar]
  • 28.Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord. 2002;12(Suppl 1):S169–S174. doi: 10.1016/S0960-8966(02)00097-4. [DOI] [PubMed] [Google Scholar]
  • 29.Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2002;12:917–925. doi: 10.1016/S0960-8966(02)00180-3. [DOI] [PubMed] [Google Scholar]
  • 30.Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil. 2005;86:284–288. doi: 10.1016/j.apmr.2004.04.021. [DOI] [PubMed] [Google Scholar]
  • 31.Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve. 2003;27:222–7. doi: 10.1002/mus.10319. [DOI] [PubMed] [Google Scholar]
  • 32.Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy.Pediatr Cardiol 2005. [DOI] [PubMed]
  • 33.Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord. 1991;1:261–266. doi: 10.1016/0960-8966(91)90099-E. [DOI] [PubMed] [Google Scholar]
  • 34.Angelini C, Pegoraro E, Perini F, Turella E, Intino M, Pini A, et al. A trial with a new steroid in Duchenne Muscular Dystrophy. In: Angelini C, Danieli GA, Fontanari D, et al., editors. Muscular dystrophy research. New York, NY: Elsevier; 1991. pp. 173–179. [Google Scholar]
  • 35.Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 1994;17:386–391. doi: 10.1002/mus.880170405. [DOI] [PubMed] [Google Scholar]
  • 36.Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138:45–50. doi: 10.1067/mpd.2001.109601. [DOI] [PubMed] [Google Scholar]
  • 37.Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004;14(8–9):476–482. doi: 10.1016/j.nmd.2004.05.001. [DOI] [PubMed] [Google Scholar]
  • 38.Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol. 2003;3:7–7. doi: 10.1186/1471-2377-3-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol. 2003;91:769–772. doi: 10.1016/S0002-9149(02)03429-X. [DOI] [PubMed] [Google Scholar]
  • 40.Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23:1344–1347. doi: 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 41.Moxley RT, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64:13–20. doi: 10.1212/01.WNL.0000148485.00049.B7. [DOI] [PubMed] [Google Scholar]
  • 42.Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56:1075–1079. doi: 10.1212/WNL.56.8.1075. [DOI] [PubMed] [Google Scholar]
  • 43.Kissel JT, Burrow KL, Rammohan KW, Mendell JR. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology. 1991;41:667–672. doi: 10.1212/WNL.41.5.667. [DOI] [PubMed] [Google Scholar]
  • 44.Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT, et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology. 1993;43(3):532–536. doi: 10.1212/WNL.43.3_Part_1.532. [DOI] [PubMed] [Google Scholar]
  • 45.Fisher I, Abraham D, Bouri K, Hoffman EP, Muntoni F, Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. Faseb J. 2005;19:834–836. doi: 10.1096/fj.04-2511fje. [DOI] [PubMed] [Google Scholar]
  • 46.Tinsley JM, Blake DJ, Pearce M, Knight AE, Kendrick-Jones J, Davies KE. Dystrophin and related proteins. Curr Opin Genet Dev. 1993;3:484–490. doi: 10.1016/0959-437X(93)90124-8. [DOI] [PubMed] [Google Scholar]
  • 47.Stupka N, Gregorevic P, Plant DR, Lynch GS. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol (Berl) 2004;107:299–310. doi: 10.1007/s00401-003-0807-x. [DOI] [PubMed] [Google Scholar]
  • 48.De Luca A, Nico B, Liantonio A, Didonna MP, Fraysse B, Pierno S, et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol. 2005;166:477–489. doi: 10.1016/S0002-9440(10)62270-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology. 1993;43(3):527–532. doi: 10.1212/WNL.43.3_Part_1.527. [DOI] [PubMed] [Google Scholar]
  • 50.Anderson JE, McIntosh LM, Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve. 1996;19:1576–1585. doi: 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  • 51.Tamopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology. 1999;52:854–857. doi: 10.1212/WNL.52.4.854. [DOI] [PubMed] [Google Scholar]
  • 52.Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002;12:174–182. doi: 10.1016/S0960-8966(01)00273-5. [DOI] [PubMed] [Google Scholar]
  • 53.Tamopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004;62:1771–1777. doi: 10.1212/01.WNL.0000125178.18862.9D. [DOI] [PubMed] [Google Scholar]
  • 54.Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, Ramonatxo M, et al. L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis. 2005;20:123–130. doi: 10.1016/j.nbd.2005.02.010. [DOI] [PubMed] [Google Scholar]
  • 55.Chaubourt E, Voisin V, Fossier P, Baux G, Israel M, De La Porte S. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris. 2002;96(1–2):43–52. doi: 10.1016/S0928-4257(01)00079-1. [DOI] [PubMed] [Google Scholar]
  • 56.Barton ER, Morris L, Kawana M, Bish LT, Toursel T. Systemic administration of L-arginine benefits mdx skeletal muscle function.Muscle Nerve 2005. [DOI] [PubMed]
  • 57.Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J, et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice.Muscle Nerve 2005. [DOI] [PubMed]
  • 58.Patel K, Amthor H. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord. 2005;15:117–126. doi: 10.1016/j.nmd.2004.10.018. [DOI] [PubMed] [Google Scholar]
  • 59.McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83–90. doi: 10.1038/387083a0. [DOI] [PubMed] [Google Scholar]
  • 60.Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682–2688. doi: 10.1056/NEJMoa040933. [DOI] [PubMed] [Google Scholar]
  • 61.Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418–421. doi: 10.1038/nature01154. [DOI] [PubMed] [Google Scholar]
  • 62.Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002;52:832–836. doi: 10.1002/ana.10385. [DOI] [PubMed] [Google Scholar]
  • 63.Benabdallah BF, Bouchentouf M, Tremblay JP. Improved success of myoblast transplantation in mdx mice by blocking the myostatin signal. Transplantation. 2005;79:1696–1702. doi: 10.1097/01.TP.0000167379.27872.2B. [DOI] [PubMed] [Google Scholar]
  • 64.Partridge TA, Grounds M, Sloper JC. Evidence of fusion between host and donor myoblasts in skeletal-muscle grafts. Nature. 1978;273:306–308. doi: 10.1038/273306a0. [DOI] [PubMed] [Google Scholar]
  • 65.Watt DJ, Lambert K, Morgan JE, Partridge TA, Sloper JC. Incorporation of donor muscle precursor cells into an area of muscle regeneration in the host mouse. J Neurol Sci. 1982;57(2–3):319–331. doi: 10.1016/0022-510X(82)90038-7. [DOI] [PubMed] [Google Scholar]
  • 66.Watt DJ, Morgan JE, Partridge TA. Use of mononuclear precursor cells to insert allogeneic genes into growing mouse muscles. Muscle Nerve. 1984;7:741–750. doi: 10.1002/mus.880070908. [DOI] [PubMed] [Google Scholar]
  • 67.Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature. 1989;337:176–179. doi: 10.1038/337176a0. [DOI] [PubMed] [Google Scholar]
  • 68.Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, et al. Myoblast transfer in the treatment of Duchenne’s muscular dystrophy. N Engl J Med. 1995;333:832–838. doi: 10.1056/NEJM199509283331303. [DOI] [PubMed] [Google Scholar]
  • 69.Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Lanctot AM, et al. Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve. 1997;20:469–478. doi: 10.1002/(SICI)1097-4598(199704)20:4<469::AID-MUS10>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  • 70.Law PK. Myoblast transfer therapy. Lancet. 1993;341:8839–8839. doi: 10.1016/0140-6736(93)90115-W. [DOI] [PubMed] [Google Scholar]
  • 71.Law PK, Goodwin TG, Fang Q, Hall TL, Quinley T, Vastagh G, et al. First human myoblast transfer therapy continues to show dystrophin after 6 years. Cell Transplant. 1997;6:95–100. doi: 10.1016/S0963-6897(96)00138-8. [DOI] [PubMed] [Google Scholar]
  • 72.Partridge T. Myoblast transplantation. Neuromuscul Disord. 2002;12(Suppl 1):S3–S6. doi: 10.1016/S0960-8966(02)00076-7. [DOI] [PubMed] [Google Scholar]
  • 73.Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest. 2002;110:807–814. doi: 10.1172/JCI16098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Bittner RE, Schofer C, Weipoltshammer K, Ivanova S, Streubel B, Hauser E, et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat Embryol (Berl) 1999;199:391–396. doi: 10.1007/s004290050237. [DOI] [PubMed] [Google Scholar]
  • 75.Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999;401:390–394. doi: 10.1038/43919. [DOI] [PubMed] [Google Scholar]
  • 76.Wilton SD, Dye DE, Blechynden LM, Laing NG. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul Disord. 1997;7:329–335. doi: 10.1016/S0960-8966(97)00058-8. [DOI] [PubMed] [Google Scholar]
  • 77.Ferrari G, Mavilio F. Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy? Neuromuscul Disord. 2002;12(Suppl 1):S7–S10. doi: 10.1016/S0960-8966(02)00102-5. [DOI] [PubMed] [Google Scholar]
  • 78.Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996;93:5731–5736. doi: 10.1073/pnas.93.12.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.van Deutekom JC, van Ommen GJ. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003;4:774–783. doi: 10.1038/nrg1180. [DOI] [PubMed] [Google Scholar]
  • 80.Dubowitz V. Special Centennial Workshop-101st ENMC International Workshop: Therapeutic Possibilities in Duchenne Muscular Dystrophy, 30th November–2nd December 2001, Naarden, The Netherlands. Neuromuscul Disord. 2002;12:421–431. doi: 10.1016/S0960-8966(02)00006-8. [DOI] [PubMed] [Google Scholar]
  • 81.Akkaraju GR, Huard J, Hoffman EP, Goins WF, Pruchnic R, Watkins SC, et al. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J Gene Med. 1999;1:280–289. doi: 10.1002/(SICI)1521-2254(199907/08)1:4<280::AID-JGM45>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  • 82.Huard J, Krisky D, Oligino T, Marconi P, Day CS, Watkins SC, et al. Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord. 1997;7:299–313. doi: 10.1016/S0960-8966(97)00054-0. [DOI] [PubMed] [Google Scholar]
  • 83.Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253–261. doi: 10.1038/nm0302-253. [DOI] [PubMed] [Google Scholar]
  • 84.Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA. 2000;97:13714–13719. doi: 10.1073/pnas.240335297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Athanasopoulos T, Graham IR, Foster H, Dickson G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD) Gene Ther. 2004;11(Suppl 1):S109–S121. doi: 10.1038/sj.gt.3302379. [DOI] [PubMed] [Google Scholar]
  • 86.Goncalves MA, van Nierop GP, Tijssen MR, Lefesvre P, Knaan-Shanzer S, van der Velde I, et al. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol. 2005;79:3146–3162. doi: 10.1128/JVI.79.5.3146-3162.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Kapsa R, Kornberg AJ, Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol. 2003;2:299–310. doi: 10.1016/S1474-4422(03)00382-X. [DOI] [PubMed] [Google Scholar]
  • 88.Braun S, Thioudellet C, Rodriguez P, Ali-Hadji D, Perraud F, Accart N, et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther. 2000;7:1447–1457. doi: 10.1038/sj.gt.3301261. [DOI] [PubMed] [Google Scholar]
  • 89.Romero NB, Braun S, Benveniste O, Leturcq F, Hogrel JY, Morris GE, et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther. 2004;15:1065–1076. doi: 10.1089/hum.2004.15.1065. [DOI] [PubMed] [Google Scholar]
  • 90.Rando TA, Disatnik MH, Zhou LZ. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A. 2000;97:5363–5368. doi: 10.1073/pnas.97.10.5363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.van Deutekom JC. Gene therapy: the ‘pro-sense’ approach to Duchenne muscular dystrophy. Eur J Hum Genet. 2005;13:518–519. doi: 10.1038/sj.ejhg.5201381. [DOI] [PubMed] [Google Scholar]
  • 92.Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 2003;9:1009–1014. doi: 10.1038/nm897. [DOI] [PubMed] [Google Scholar]
  • 93.Muntoni F, Bushby K, van Ommen G. 128th ENMC International Workshop on ‘Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy’ 22–24 October 2004, Naarden, The Netherlands. Neuromuscul Disord. 2005;15:450–457. doi: 10.1016/j.nmd.2005.02.007. [DOI] [PubMed] [Google Scholar]
  • 94.Wells DJ, Ferrer A, Wells KE. Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy. Expert Rev Mol Med. 2002;2002:1–23. doi: 10.1017/S146239940200515X. [DOI] [PubMed] [Google Scholar]
  • 95.Wilton SD, Fletcher S. Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now? Neuromuscul Disord. 2005;15:399–402. doi: 10.1016/j.nmd.2005.03.003. [DOI] [PubMed] [Google Scholar]
  • 96.Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104:375–381. doi: 10.1172/JCI7866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol. 2001;49:706–711. doi: 10.1002/ana.1023. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES